AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02041377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karajishi TS Investigational Blood Glucose Monitoring System
Description: Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
Study NCT04421625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test for SARS-Cov2 for patients and health staff
Description: Diagnostic test for SARS-CoV2 :~* Blood test to analyse the IgG and IgM with an immediate qualitative analysis (serological test) and a differed quantitative analysis (ELISA test)~* Results of nasal swab that will allow extracting the RNA and realizing a RT-PCR (only if the participants present symptoms). It will be obtained by standard local laboratories.~* Questionnaires (based on serology, clinic, economy (socio-demographic and lifestyle questionnaire) and epidemiology)
Study NCT04848922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot shower intervention
Description: Intervention group took a shower in a standing position at a water temperature of 37-41°C for 10-20 minutes between 6 and 12 hours after vaginally birth.
Study NCT00369356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Bare metal stenting with administration of oral prednisone as described in the protocol
Study NCT00369356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting coronary stent
Description: Stenting with DES (Cypher or Taxus)
Study NCT00369356 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bare metal coronary stent
Description: Stenting with BMS only
Study NCT01662895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
Study NCT01662895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
Study NCT00645983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile Extract
Description: 220 mg - 1100 mg daily
Study NCT00645983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 5 capsules daily
Study NCT02353533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: over- the- scope full- thickness resection device (FTRD)
Description: Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
Study NCT02353533 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EMR
Description: Standard endoscopic mucosal resection using a resection snare
Study NCT03521505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine arm
Description: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5\~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3\~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration
Study NCT03521505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol arm
Description: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3\~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration.
Study NCT01537211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C leg compared to subject's mechanical leg (Otto Bock)
Description: comparison of different prosthetic knees
Study NCT00961883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-B
Description: New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU
Study NCT00961883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for injection, delivered intramuscularly
Study NCT00961883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU
Study NCT00961883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^9 PFU
Study NCT00961883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^8 PFU
Study NCT01515657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 Aspirin Capsules
Description: 325 mg aspirin; once per day for 3 days
Study NCT01515657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-Release Aspirin Tablets
Description: 325 mg aspirin; once per day for 3 days
Study NCT01515657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated aspirin caplets
Description: 325 mg aspirin; once per day for 3 days
Study NCT06106854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: SystemCHANGE
Description: six-month SystemCHANGE™ intervention
Study NCT06106854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Six patient education booklets
Study NCT03958552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
Study NCT02849132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: oral entecavir 0.5mg daily for 8 years
Study NCT02357498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transsphenoidal surgery
Study NCT02962050 — intervention group
Intervention type: PROCEDURE
Intervention: Videofluoroscopic Swallowing Study (VFSS)
Description: Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
Study NCT02962050 — intervention group
Intervention type: DEVICE
Intervention: Voluntary Peak Cough Flow Testing
Description: Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
Study NCT02962050 — intervention group
Intervention type: DEVICE
Intervention: Iowa Oral Performance Instrument
Description: The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
Study NCT02962050 — intervention group
Intervention type: DRUG
Intervention: Capsaicin Challenge
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
Study NCT02962050 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary Function Testing
Description: Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
Study NCT02962050 — intervention group
Intervention type: OTHER
Intervention: Eating Assessment Tool 10
Description: The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
Study NCT02962050 — intervention group
Intervention type: OTHER
Intervention: The Center for Neurologic Study Bulbar Function Scale
Description: The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
Study NCT00488384 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemopreventive application (Acitretin)
Description: Chemopreventive application (Acitretin)
Study NCT02007174 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Study NCT02007174 — intervention group
Intervention type: DRUG
Intervention: Medical Treatment
Description: Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
Study NCT02007174 — intervention group
Intervention type: PROCEDURE
Intervention: Argon laser treatment
Study NCT03345472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation System
Description: Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
Study NCT02481973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Homoeopathic Remedy
Description: Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
Study NCT01399580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
Study NCT01399580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
Study NCT02148237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
Study NCT03516760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM333
Description: infusion of GEM333; administered intravenously and continuously over 10 days
Study NCT02925130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
Study NCT02925130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute oral intake of a placebo drug
Study NCT04136431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programed cryotherapy and continuous passive motion
Description: The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
Study NCT04136431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unrogramed cryotherapy and continuous passive motion
Description: A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
Study NCT02870855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrauterine injection of HCG
Description: intrauterine injection of HCG berore blastocyst transfer
Study NCT02330848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Calorie controlled
Description: The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
Study NCT02400957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver nanoparticles
Description: Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
Study NCT02400957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
Study NCT01572948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: roflumilast
Description: The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
Study NCT01572948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
Study NCT04025203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb.
Study NCT04025203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine
Description: Oral tablets
Study NCT04025203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: oral capsules
Study NCT02067364 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fit & Function test
Study NCT05134961 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreaduodenectomy and possible adjuvant therapy
Description: Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
Study NCT03527563 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet Medical Model
Description: Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
Study NCT02105532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive transfusion policy
Description: Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
Study NCT02105532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Transfusion Policy
Description: Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
Study NCT01936532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months.
Study NCT01936532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01936532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02127190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10 emulsion
Description: CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
Study NCT02127190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02646527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
Study NCT00353418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: 180 µg subcutaneously weekly for 48 weeks
Study NCT00353418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 µg subcutaneously weekly for 48 weeks
Study NCT00353418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800 mg orally daily for 48 weeks
Study NCT00353418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
Study NCT01225679 — intervention group
Intervention type: DEVICE
Intervention: positive airway pressure, Non-invasive mechanic ventilation
Description: Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O.
Study NCT01576692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized anti-GD2 antibody
Description: A maximum of 6 courses of therapy may be given on the following schedule:~* Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~* Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~* Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m\^2)/dose, over 4 hours daily~* NK Cell dosage: minimum of 0.1 \* 10\^6 cells/kg; maximum of 400 \* 10\^6 CD45+ cells/kg, given once
Study NCT01576692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3
Study NCT01576692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytokines
Description: Cytokines may be given at the following dosages:~* interleukin-2: 1 million units/m\^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~* GM-CSF: 250 mcg/m\^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC >2,000/mm\^3